Hand Eczema Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Arcutis Biotherapeutics, Asana BioSciences

Hand Eczema Pipeline constitutes 5+ key companies continuously working towards developing 5+ Hand Eczema treatment therapies, analyzes DelveInsight.

Hand Eczema Overview:

Hand eczema is a prevalent and widespread skin condition that was likely first documented in the 19th century. It affects individuals across various occupations and can result from a combination of internal (endogenous) and external (environmental) factors. These factors may act independently or together in contributing to the condition.

In the 19th century, dermatologists identified multiple morphological variants of hand eczema, including eczema solare, rubrum, impetiginoides, squamosum, papulosum, and marginatum. Chronic hand eczema (CHE) is a persistent inflammatory skin disorder, affecting up to 10% of the population, particularly those in high-risk professions.

While topical treatments are the standard approach, up to 65% of cases remain unresolved after therapy. Moderate-to-severe cases are often resistant to topical treatments, requiring systemic therapies for effective management.

Request for a detailed insights report on Hand Eczema pipeline insights @ https://www.delveinsight.com/report-store/chronic-hand-eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Hand Eczema Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hand Eczema Therapeutics Market.

Key Takeaways from the Hand Eczema Pipeline Report

DelveInsight's Hand Eczema pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Hand Eczema treatment.
Key Hand Eczema companies such as Arcutis Biotherapeutics, Asana BioSciences, and others are evaluating new drugs for Hand Eczema to improve the treatment landscape.
Promising Hand Eczema pipeline therapies in various stages of development include ARQ-252, ASN002, and others.

Recent breakthroughs in the Hand Eczema Pipeline Segment:

In March 2023, the European Commission approved delgocitinib cream for treating chronic hand eczema in adults. This topical Janus kinase (JAK) inhibitor demonstrated significant efficacy in clinical trials, offering a new option for patients unresponsive to conventional therapies.
In September 2021, the U.S. Food and Drug Administration (FDA) approved ruxolitinib cream for the treatment of mild to moderate atopic dermatitis, which includes cases of hand eczema. This topical JAK inhibitor provides an alternative for patients who do not respond adequately to topical corticosteroids.

Hand Eczema Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hand Eczema Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hand Eczema treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hand Eczema market.

Download our free sample page report on Hand Eczema pipeline insights @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hand Eczema Emerging Drugs

ARQ-252: Arcutis Biotherapeutics
ASN002: Asana BioSciences

Hand Eczema Companies

More than five key companies are actively developing therapies for Chronic Hand Eczema. Among them, Arcutis Biotherapeutics has a drug candidate that has progressed to the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hand Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Hand Eczema Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Hand Eczema Therapies and Key Companies: Hand Eczema Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chronic-hand-eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hand Eczema Pipeline Therapeutic Assessment
• Hand Eczema Assessment by Product Type
• Hand Eczema By Stage
• Hand Eczema Assessment by Route of Administration
• Hand Eczema Assessment by Molecule Type

Download Hand Eczema Sample report to know in detail about the Hand Eczema treatment market @ Hand Eczema Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Hand Eczema Current Treatment Patterns
4. Hand Eczema - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hand Eczema Late-Stage Products (Phase-III)
7. Hand Eczema Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hand Eczema Discontinued Products
13. Hand Eczema Product Profiles
14. Hand Eczema Key Companies
15. Hand Eczema Key Products
16. Dormant and Discontinued Products
17. Hand Eczema Unmet Needs
18. Hand Eczema Future Perspectives
19. Hand Eczema Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Hand Eczema Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chronic-hand-eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.